Sartorius
5 Orville Drive, Suite 200
Bohemia
New York
11717
United States
70 articles with Sartorius
-
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
-
BioNet and Sartorius’ Company BIA Separations Collaborate on Production Process Development of mRNA Vaccines
11/2/2021
BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, announced the successful development of an optimized mRNA manufacturing process.
-
Sartorius grows dynamically and profitably - Substantial double-digit increases in sales and earnings
10/20/2021
The life science group Sartorius has continued to grow dynamically and profitably. For the nine-month reporting period of 2021, the company listed on the DAX since September recorded significant double–digit growth rates in sales and earnings.
-
Matica Bio Announces Joint Research Agreement with Sartorius for the Development of Advanced Viral Vector Manufacturing Technology
10/18/2021
Matica Biotechnology, Inc today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry.
-
Marked by recent announcements of new manufacturing sites, headquarters and job creations, the life science industry continues to thrive despite the COVID-19 pandemic.
-
Sartorius acquires cell culture specialist Xell AG
7/29/2021
The life science company Sartorius, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany.
-
Sartorius continues on its fast growth trajectory - significant double-digit increases in sales and earnings
7/21/2021
The life science Group Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake.
-
Sartorius provides preliminary first-half financial key figures and raises forecast for 2021
7/5/2021
Sartorius announces that it expects strong first–half performance and raises its forecast for the full year of 2021.
-
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
-
Sartorius with first-quarter uptick 2021 in sales and earnings
4/21/2021
The life science group Sartorius had an exceptionally strong start in fiscal 2021 and grew substantially in order intake1, sales revenue and earnings.
-
Penn State's Industrial Biotechnology Ecosystem Continues to Bloom
4/13/2021
In just 30 months and despite facing a global pandemic, Penn State and collaborating companies have successfully established and advanced the industrial biotechnology ecosystem and talent pipeline at the university.
-
Resolutions of the Annual Shareholders' Meeting of Sartorius AG - Mar 26, 2021
3/26/2021
At virtual Annual General Shareholders' Meeting, shareholders granted discharge to the Executive Board and the Supervisory Board and approved the boards' proposals by a large majority.
-
Sartorius looks back on a very successful 2020 and expects further strong growth
2/18/2021
The life science group Sartorius confirmed its preliminary figures for 2020 upon the release of its annual report.
-
Sartorius closes 2020 with strong growth to well over 2 billion euros and a further increase in profitability
1/27/2021
Preliminary results for the full year of 2020: Order intake up 49.0 percent; sales revenue up 30.2 percent; underlying EBITDA margin climbs to 29.6 percent
-
Sartorius to acquire Novasep's chromatography process equipment division
1/6/2021
The life science company Sartorius announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep.
-
Sartorius Awards MyoGene Bio With $25,000 in Products and Services at QB3 Pitch Summit 2020
12/16/2020
Sartorius recently recognized startup company MyoGene Bio at the QB3 Pitch Summit, a competition showcasing promising new life science companies. This award provides the company with a $25,000 voucher that they can use for the purchase of any Sartorius products and services to support their development of a gene therapy for Duchenne muscular dystrophy (DMD). MyoGene Bio’s MyoDys 45-55 gene editing therapy uses CRISPR
-
Sartorius acquires filtration expert WaterSep BioSeparations
12/9/2020
- Transaction provides a complementary fit with Sartorius' separation portfolio, adding innovative crossflow filtration units for easy-to-use bioprocessing devices - Technology is especially suited to gene and cell therapy applications, vaccine production and intensified bioprocessing
-
Sartorius closes acquisition of BIA Separations
11/2/2020
The life science company Sartorius successfully closed the acquisition of the Slovenian purification specialist BIA Separations.
-
Strong profitable growth at Sartorius
10/20/2020
Nine-month results: Order intake1 up 37.8 percent; sales revenue up 25.2 percent; underlying EBITDA1 margin climbs to 29.1 percent
-
Purification specialist BIA Separations to become part of Sartorius
10/2/2020
The life science company Sartorius announced it has entered into a definitive agreement to merge purification specialist BIA Separations into its subgroup Sartorius Stedim Biotech in a transaction totaling 360 million euros of which 240 million euros will be paid in cash and 120 million euros in Sartorius Stedim Biotech shares.